Elena Olmastroni

Dr. Elena Olmastroni

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2021 in Nature Reviews Cardiology
Verified
Journal Article
Closed access
PDF file
APAngela Pirillo
Angela Pirillo
MCManuela Casula
Manuela Casula
EOElena Olmastroni
Elena Olmastroni
GNGiuseppe D. Norata
Giuseppe D. Norata
Alberico Luigi Catapano‌Alberico Luigi Catapano‌
Alberico Luigi Catapano‌

1 October 2018 in Atherosclerosis
Verified
Journal Article
Closed access
MCManuela Casula
Manuela Casula
EOElena Olmastroni
Elena Olmastroni
APAngela Pirillo
Angela Pirillo
Alberico Luigi Catapano‌Alberico Luigi Catapano‌
Alberico Luigi Catapano‌
MAMarcello Arca
Marcello Arca
VZVeronica Zampoleri
Veronica Zampoleri

19 February 2024 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
SXSining Xie
Sining Xie
FGFederica Galimberti
Federica Galimberti
EOElena Olmastroni
Elena Olmastroni
TLThomas F Luscher
Thomas F Luscher
Stefano CarugoStefano Carugo
Stefano Carugo
MLMichael Louie
Michael Louie
Chronic low-degree inflammation is a hallmark of atherosclerotic cardiovascular (CV) disease. To assess the effect of lipid-lowering therapies on C-reactive protein (CRP), a biomarker of inflammation, we conducted a meta-analysis according to the PRISMA guidelines. Databases were searched from inception to July 2023. Inclusion criteria were: (i) randomized controlled trials (RCTs) in human, Phase II, III, or IV; (ii) English language; (iii) comparing the effect of lipid-lowering drugs vs. placebo; (iv) reporting the effects on CRP levels; (v) with intervention duration of more than 3 weeks; (vi) and sample size (for both intervention and control group) over than 100 subjects. The between-group (treatment-placebo) CRP absolute mean differences and 95% confidence intervals were calculated for each drug class separately. A total of 171 668 subjects from 53 RCTs were included. CRP levels (mg/L) were significantly decreased by statins [−0.65 (−0.87 to −0.43), bempedoic acid; −0.43 (−0.67 to −0.20), ezetimibe; −0.28 (−0.48 to −0.08)], and omega-3 fatty acids [omega3FAs, −0.27 (−0.52 to −0.01)]. CRP was reduced by −0.40 (−1.17 to 0.38) with fibrates, although not statistically significant. A slight increase of CRP concentration was observed for proprotein convertase subtilisin/kexin type 9 inhibitors [0.11 (0.07–0.14)] and cholesteryl-ester transfer protein inhibitors [0.10 (0.00–0.21)], the latter being not statistically significant. Meta-regression analysis did not show a significant correlation between changes in CRP and LDL cholesterol (LDL-C) or triglycerides. Statins, bempedoic acid, ezetimibe, and omega3FAs significantly reduce serum CRP concentration, independently of LDL-C reductions. The impact of this anti-inflammatory effect in terms of CV prevention needs further investigation.

EOElena Olmastroni
Elena Olmastroni
FGFederica Galimberti
Federica Galimberti
ETElena Tragni
Elena Tragni
Alberico Luigi Catapano‌Alberico Luigi Catapano‌
Alberico Luigi Catapano‌
MCManuela Casula
Manuela Casula
The spread of the coronavirus disease 2019 (COVID-19) pandemic caused a sudden and significant disruption in healthcare services, especially for patients suffering from chronic diseases. We aimed at evaluating the impact of the pandemic on adherence to chronic therapies through a systematic review of available studies. PubMed, EMBASE, and Web of Science were searched since inception to June 2022. Inclusion criteria were: (1) observational studies or surveys; (2) studies on patients with chronic diseases; (3) reporting the effects of COVID-19 pandemic on adherence to chronic pharmacological treatment, as a comparison of adherence during the pandemic period vs. pre-pandemic period (primary outcome) or as rate of treatment discontinuation/delay specifically due to factors linked to COVID-19 (secondary outcome). Findings from 12 (primary outcome) and 24 (secondary outcome) studies showed that many chronic treatments were interrupted or affected by a reduced adherence in the pandemic period, and that fear of infection, difficulty in reaching physicians or healthcare facilities, and unavailability of medication were often reported as reasons for discontinuation or modification of chronic therapies. For other therapies where the patient was not required to attend the clinic, continuity of treatment was sometimes ensured through the use of telemedicine, and the adherence was guaranteed with drug stockpiling. While the effects of the possible worsening of chronic disease management need to be monitored over time, positive strategies should be acknowledged, such as the implementation of e-health tools and the expanded role of community pharmacists, and may play an important role in preserving continuity of care for people with chronic diseases.

13 May 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
EMElisa Mattavelli
Elisa Mattavelli
EOElena Olmastroni
Elena Olmastroni
Daniela BonofiglioDaniela Bonofiglio
Daniela Bonofiglio
Alberico Luigi Catapano‌Alberico Luigi Catapano‌
Alberico Luigi Catapano‌
Andrea BaragettiAndrea Baragetti
Andrea Baragetti
Paolo MagniPaolo Magni
Paolo Magni
The Mediterranean diet has emerged as a comprehensive lifestyle, including specific foods and meal composition and a set of behavioural and social features. Adherence to the Mediterranean diet has been shown to promote health and reduce the prevalence of chronic diseases. The actual implementation of the Mediterranean diet is affected by several sociocultural factors as well as geographical components. Indeed, the geographical location, such as a specific country or different areas in a country and specific latitude and climate, appears to be an important factor that may strongly affect the implementation of the Mediterranean diet or some of its principles as well as the adherence to it. Another dynamic component affecting personal nutritional choices, also regarding adherence to the Mediterranean diet and its principles, is the individual life-long trajectory of food preference and nutrition habits and awareness. In this review, we discuss the current evidence on the impact of geographical location on adherence to the Mediterranean diet.

1 May 2020 in Pharmacological Research
Verified
Journal Article
Closed access
EOElena Olmastroni
Elena Olmastroni
MBMezio T. Boccalari
Mezio T. Boccalari
ETElena Tragni
Elena Tragni
Federico ReaFederico Rea
Federico Rea
LMLuca Merlino
Luca Merlino
MCManuela Casula
Manuela Casula